While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > COLUMN
COLUMN
-
Leading from Afar
October 22, 2012
-
“Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
-
Our Habits Determine Our Success
August 8, 2012
-
Marketing Is More than a Pen and a Tissue Box
July 9, 2012
-
Science without Works Is Dead
June 4, 2012
-
Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
-
The Eight Characteristics of a Great Leader
April 2, 2012
-
Maurer’s Healthcare Insight (143)
March 26, 2012
-
Maurer’s Healthcare Insight (142)
February 27, 2012
-
Maurer’s Healthcare Insight (141)
January 30, 2012
-
Maurer’s Healthcare Insight (140)
December 26, 2011
-
Maurer’s Healthcare Insight (139)
December 12, 2011
-
Maurer’s Healthcare Insight (138)
November 21, 2011
-
Maurer’s Healthcare Insight（137）
October 17, 2011
-
Maurer’s Healthcare Insight (136)
September 12, 2011
-
Maurer's Healthcare Insight (135)
August 15, 2011
-
Maurer's Healthcare Insight (134)
August 1, 2011
-
Maurer's Healthcare Insight (133)
July 11, 2011
-
Maurer's Healthcare Insight (132)
May 30, 2011
-
Maurer's Healthcare Insight (131)
April 18, 2011
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…